Good morning and thank you for standing by. Welcome to the First Quarter 2024 Haemonetics Corporation's Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Olga Guyette, Senior Director, Investor Relations & Treasury. Please go ahead.

Good morning, everyone. Thank you for joining us for Haemonetics first quarter fiscal 2024 conference call and webcast. I'm joined today by Chris Simon, our CEO; and James D'Arecca, our CFO. This morning, we posted our first fiscal 2024 results to our Investor Relations website, along with our updated fiscal 2024 guidance. Before we begin, just a quick reminder that all revenue growth rates discussed today are organic and exclude the impact of currency fluctuations. We'll also refer to other non-GAAP financial measures to help investors understand Haemonetics' ongoing business performance. Please note that these measures exclude certain charges and income items. For a full list of excluded items, reconciliations are GAAP results and comparisons with the prior year periods, please refer to our first quarter fiscal 2024 earnings release available in our website. Our remarks today include forward-looking statements, and our actual results may differ materially from the anticipated results. Factors that may cause our results to differ include those referenced in the Safe Harbor statement in today's release and in our other SEC filings. We do not undertake any obligation to update these forward-looking statements. And now, I'd like to turn it over to Chris.

Thanks Olga. Good morning and thank you all for joining. Today, we reported first quarter organic revenue growth of 21%, and adjusted earnings per diluted share of $1.05, 81% growth over prior year. It was a particularly strong start to the year with market leading performance across our businesses, delivering revenue growth and adjusted operating margin expansion, while advancing meaningful innovation and commercial milestones. Our Operational Excellence Program improves productivity and strengthens risk management, enabling us to fulfill customer's demands, expand our margins, and invest in opportunities for further growth and value creation. We are pleased that Diane Bryant has joined Haemonetics Board of Directors. She brings more than 30 years of leadership experience with top global technology organizations, including Google, Intel, and NovaSignal. We welcome her counsel and expertise in technology solutions and healthcare information management. Turning now to our business unit results. Plasma revenue grew 35% in the first quarter. North America disposables grew 41%, disproportionately driven by strong momentum in U.S. collections and price. Additionally, our first quarter Plasma revenue growth rate benefited from unfavorable order timing in the first quarter of fiscal 2023. In the U.S., this was the seventh consecutive quarter of volume growth exceeding historical seasonality. We also saw strong high single digit collections growth in Europe. Our NexSys Plasma collection system stands apart for offering 9% to 12% additional plasma yield, impeccable safety, connectivity and a superior donor experience backed by real-world evidence from tens of millions of collections. We are bringing powerful innovation with FDA clearance of a redesigned bowl and the Express Plus software to shorten average collection time, optimize plasma center efficiency and reduced cost per liter. This technology is expected to enable an average procedure time of 33 to 38 minutes, approximately a 20% reduction from the current procedure…

Thank you, Chris and good morning, everyone. In the first quarter of fiscal 2024, our business demonstrated continued strength. First quarter adjusted gross margin was 54.2%, 100 basis points lower than in the same period of the prior year. Our adjusted gross margins benefited from price, volume and favorable geographic and product mix, as we continue to experience strong momentum in Plasma and Hospital, particularly in the U.S. and benefited from favorable order timing in Blood Center. These benefits were more than offset by a $3.4 million inventory reserve due to a voluntary product recall in our Whole Blood business, upfront investments in operations to meet the unprecedented demand for our products and higher depreciation expense. Adjusted operating expenses in the first quarter were $98.5 million, flat compared with the first quarter of the prior year. We benefited from additional savings from the Operational Excellence Program and improving logistics costs that fully funded additional growth investments in the quarter. As a percentage of revenue, adjusted operating expenses were 31.7% in the first quarter of fiscal 2024 compared with 38.1% in the same period of the prior year. Our first quarter adjusted operating income was $70.2 million, an increase of $25 million or 56%. As a percentage of revenue, adjusted operating margin was 22.6% in the first quarter, up 540 basis points compared with the same period in fiscal 2023. The expansion in the adjusted operating margin was driven by higher operating leverage from our business and improving macroeconomic trends. The operating leverage we experienced in our quarter was ahead of our expectations, particularly due to stronger-than-anticipated momentum in Plasma, favorable order timing in blood center and improved logistics costs. As we look at the remainder of the year, we acknowledge a challenging macro environment and anticipated impact from changes in…

Thank you. [Operator Instructions] Our first question comes from Anthony Petrone with Mizuho Americas. Your line is open.

All right. Thanks and good morning, everyone. Congratulations on a strong start to the fiscal year. Maybe a couple for Chris on plasma, and then I'll follow up with Jim on margins. Maybe, Chris, just kind of the experience in the quarter here. You mentioned, obviously, volumes are still running ahead of the historical collection trend, but maybe just where do you think we are in the inventory replenishment cycle amongst the fractionators. And then maybe a couple of follow-ups on Express Plus tech. Just maybe a little bit on what is the upgrade path? Is it a pure software upgrade? Or is there a capital component to that as well? And then I'll have the follow-up for Jim.

Good morning, Anthony. Thanks for joining, and thanks for the question. Yeah. This is our seventh consecutive quarter where the actual demand for plasma collections has outpaced the historical growth. Clearly, our best first quarter for plasma on record. Usually, that's our softest quarter for the year just due to some seasonal factors and we'll see how that plays out over the course of the year. We think we're still in the early stages of this recovery. When we do our back-of-the-envelope estimates around inventory levels, we think there is a meaningful way to go to get to pre-pandemic levels, which would be safe. And given the challenges that our customers experienced meeting customer needs and the criticality of meeting those needs, we think that the robustness that we're seeing will continue, which is what gave us confidence to raise our guidance for the year in plasma after only one quarter. But we feel quite good about it. We think that from the conversations we're having with customers, we think this trend will continue strongly. In terms of the new enhancements, really excited by able to get this together and get the approval, the release from FDA. It is a combination of software in the device itself, change in the disposables and then some engineering around that. It's not a particularly complicated upgrade with regards to capital or the outlay. It is meaningful for the centers. It will require some change in SOP. And given the speed with which we are now moving, we want to be thoughtful about this. So, we're talking about a limited market release, working hand-in-hand with a small group of customers, collect some real-world data further validate the claims we're making, and then move to full market release later this fiscal year. But we're going to do so without disruption. We're going to do so jointly with our customers. And as always, we will go as fast as they're prepared to go on this.

That's helpful. And then Jim, maybe just a little bit on the gross margin jump sequentially. How much of that was a runoff of higher cost inventories and price was mentioned a few times here in the press release, prepared remarks. Just maybe a recap of where price is coming in these days. And again, congratulations on the quarter.

Yeah. Thanks Anthony. So, yes, price did help us, and I'm comparing now to the first quarter of 2023. That was a nice bump up for us as well as mix really helped us on the gross margin line. Everything seemed to go in the right direction for us mix wise. We sold more in the U.S. and that bumped up our gross margin. But taking us back the other way, you saw that we had the filter recall. And we still have some of those lingering inefficiencies that I spoke about quite often last fiscal year from the run-up in volumes. We'll start to see those peel away as the year continues. But overall, it was a good start for us margin wise. And as those gross margin goes, it drops down to the operating margin for us as well, and that's why you saw such an excellent print there this quarter.

Thanks again.

Thank you. One moment for our next question. Our next question will come from Mike Matson with Needham & Company. Your line is open.

Yeah. Thanks. Great quarter, obviously. But I guess, I'm just wondering why you're not freezing the guidance more? I mean, you beat consensus by $0.32. I know you don't give quarterly guidance, but massive EPS growth versus last year, you're only raising the guidance range by about $0.15. You had tremendous operating leverage. Is there something there that you don't expect to continue for the rest of the year?

Yeah. Mike, let me start -- it's Chris. Let me start on revenue, and then I'll ask James to comment on the margin expansion. So, I think the first point I'd make is, our first quarter was really a complete effort, probably our best quarter to date. And we do think it's a preview of things to come as we actualize our LRP. We benefited significantly from strong volume in the U.S. from really the triple hit of NexSys with Persona. Those customers outpaced the rest of the field and grew disproportionately in the quarter. TEG, which had high 20s growth in the quarter, which was outstanding and then VASCADE, which was right there as well. So that trifecta helps us a lot. We do expect international growth going forward. Some of that will come at a lower gross margin. We need to be mindful of that. We talk about the macro trends. We benefited from some lower cost, but also from reduced expediting as we had a better handle on the forecast and the better ability to meet demand. And there are some below-the-line tailwinds that I'll let James speak to. It isn't that there's anything ominous pending for the remainder of the year. It is our first quarter. We want to be thoughtful about that. There are some things that we called out in our prepared remarks, for example, around blood center order timing, the uncertainty with the newly updated Russian sanctions and our whole blood filter recall that we just need to be mindful of. And then as we've talked in the past, we do expect some customer transition in the second half of the year in plasma that we need to be mindful, very difficult to anticipate the exact timing or the extent of that and therefore, we're just going to be cautious as we forecast forward. James?

Yeah. So, yes -- Mike, it's kind of early, so it's the first quarter. And I echo Chris' comment on being somewhat cautious before we would have let all that drop down -- in terms of the overperformance drop down through on the quarter. We also have some additional headwinds coming in from FX. We expect that to -- assuming the current rates stay where they are, that's another $0.10 for the rest of the year. And then also, if you noticed our tax rate in the first quarter was a bit lower for the reasons I mentioned earlier. And that will flip around on us for the back part of the year, we'll get back up to our normal recurring rate. So, when you factor all those things together, that's why the earnings guide is what you see this quarter.

Okay. I understand. And then Express Plus, I would assume that you're charging a premium for that, but I just want to make sure that was correct. So, this potentially could drive another kind of wave of price uplift as customers adopted or?

Express Plus and the speed enhancements on the procedure, Mike, are really part of a holistic plan that we have to further advance NexSys platform leadership in the market, right? We're the only ones that have the Persona Nomogram, which is we've talked about 9% to 12% yield enhancement, which is unrivaled. We did already speed up the door-to-door time, what a donor ultimately cares about, and this is a battle for donor, right? And so, donors care about, as I showed up at one time and I left at another. And so, if we can shave 15 to 20 minutes off the door-to-door time, that's meaningful for the donor. Express Plus speeds up to procedure portion of that and is additive. So, it absolutely increases our value proposition as does the bidirectional connectivity, as does a suite of donor apps that have been really well received. We started rolling those out during the pandemic and have only accelerated into that. We think about pricing holistically and you see that in our results, and you see that in our guidance going forward. We're not going to talk about the individual components for competitive reasons, but we feel we have an ability to continue to command a premium for what is a superior offering, and Express Plus is clearly part of that.

Okay. Got it. Thank you.

Thank you. Our next question -- one moment -- comes from Andrew Cooper with Raymond James. Your line is open.

Hi, everybody. Thanks for the question. Maybe just first, I know I don't necessarily want to get into a ton of detail on it. But when we think back to the prior plasma guide, the commentary was for sort of mid-teens ex- CSL, I was wondering if you could just give an update there as to sort of the impact and whether their contribution is still sort of proportionally the same as it was prior. And then I have one more follow-up as well.

Yeah. I think the base demand, particularly those customers who've adopted NexSys and doubly so those who are on NexSys with Persona are leading the charge here, Andrew, in straight numbers, we guided to the mid-teens. We would now say for those customers, we're looking at high-teens through the remainder of the year. They clearly accelerated into this opportunity as they see a bit of a benefit from some of the macroeconomic trends, Donors are showing up in large volumes and they're capitalizing on that opportunity. We don't expect that to slow down anytime soon.

Okay. Great. And then kind of sticking with a similar angle here. You mentioned demand for NexSys devices as a reason for building inventory. I guess, is that coming from new centers with existing customers? Is it competitive wins where they had been using other offerings? Can you just give us a little bit of context there on sort of the nature of it as well as maybe the magnitude of new center openings, if that is the case versus sort of the traditional historical patterns that we've seen before?

Yeah. It's predominantly new center openings. Andrew, there's -- we have share gains as well, but built into our plans, but it's predominantly new center openings to meet this uptick in demand.

Okay. And new centers have continued to behave kind of as they have pre-pandemic in terms of ramp? I know that's been a topic we've talked about before.

Yes. I think what's embedded in our guidance is very historical uptake across the new centers, those that were opened three years ago and those that are open today and everything in between. We are also seeing some improvement in the mature centers. That's been on again, off again in the fourth quarter of last year. We saw some meaningful inroads that continued through the first quarter of this year. That's a bit harder to predict, but our customers are working hard to get all of their centers full, and that includes the mature centers that have made meaningful improvements here in the first quarter.

Great. I'll stop there. Thank you.

Thank you.

Thank you. Our next question comes from Joanne Wuensch with Citi. Your line is open.

Good morning, and nice quarter. A couple of questions. SG&A as a percentage of revenue came down a lot year-over-year. And I'm just curious if this is a new go-forward run rate, if there was something in there that helped that metric, or how to think about that?

Yeah. Joanne, I'll start and then offer James want to add more to it. We continue to make investments. We are quite disciplined about breaking out our OpEx into really multiple categories. We look at sales and marketing, separate from G&A, separate from R&D and separate from freight, which is a bit of an artifact. But -- and what we saw in the quarter, we continue to invest meaningfully building out our -- particularly our sales capabilities as we take VASCADE global. So, you're going to see that. But we do that with the demand for operating leverage. We've largely held the inherent G&A cost flat, which is part of our LRP and part of the margin expansion. You see the meaningful drop off in the first quarter. That's just an artifact of paying our annual bonus and monies that were accrued for that, and then it kind of washes through. Given the outperformance that we experienced last year, we paid at the very upper end of our pay-for-performance programs. And we have a good forecast going into the year, so the accrual is just at a different level. That's really the bulk of the change.

Thank you. And then...

The freight costs as well were beneficial as those have come down. But I think the first quarter, I wouldn't say that it will be a new normal. I think it will rise from here as we go throughout the year.

Thank you. My second question has to do with the Cardiva launches outside the United States. Can you just sort of give us an update or state of the meeting, if you will, on where you are in Europe and Japan? Thanks.

Yeah. Thanks Joanne. So, in Europe, we had gotten the approval almost a year ago now, a good bit ahead of schedule. That enabled us to really accelerate our launch plans. We are building that out. It's a hybrid model. We're going to go direct where the economics of those markets and the demand clearly support that. And we'll go through distribution elsewhere. And I think the nice thing about the VASCADE family of products, initially, at least, it can be supported by third-party distributors, right? We'll lean in heavily in terms of training and development and work directly with the various clinicians to get them signed on. That's already begun in places like Germany, which is a direct market for us. Italy, which will be more of a hybrid. That's the early uptake we saw. Customer feedback in clinician and their staff has been outstanding. So that's -- we're excited there, and we're going to accelerate into that as the plan progresses. The approval in Japan is a positive development. We need to now secure reimbursement. We think that will happen here this quarter with any luck. And we'll move with a hybrid model in Japan. We've already entered into a distributor arrangement with someone who we think is a good partner to work with long-term for the Japanese market. And again, we think the VASCADE family of products, right, they are highly efficacious, but they're also quite safe. And we know they lower the cost of care by getting patients home the same day and frequently. So, we think it's a very good fit for the European and the Japanese market. The TAM there is less, but it's a good opportunity. It's a good chance for us to globalize our efforts, although that does require investment, and that's what you see flowing through our P&L.

If I can sneak one more in. Did you quantify the timing of the OUS order, the unfavorable order that you've called out?

The unfavorable OUS order...

You quantify the order timing. I guess, it was -- I have an unfavorable note, but I also -- you had some one-time timing benefit maybe.

Yeah. There are two factors, Joanne. Sorry for confusion on our end. So, we felt like the plasma, particularly the U.S. plasma comp year-over-year was a relatively easier comp because one of our large customers in the U.S. did a large onetime buy in the fourth quarter of fiscal 2022. So, there was less ordering in fiscal 2023, which is why you see such a robust quarter-on-quarter growth rate. Outside the U.S. in Blood Center, we kind of had the opposite occur, right? And so, while we had a very good first quarter in Blood Center, particularly in apheresis, we don't expect that to continue, particularly in our second quarter. And some of that is just the normal order timing. That business tends to be lumpy. But another part of it that's quite important for that business at least is Russia. And with the sanctions being rolled out, we got some preorders, particularly for platelet apheresis that we were able to meet. It's a good margin business in plasma, our good margin business in Blood Center, that probably won't repeat throughout the year and we're working hard to get our licenses. We think it's important to take our products to those markets, but we're working, obviously, within the sanctions to get that sorted. And it's just too early to tell how it's going to play forward.

Thank you.

Thank you. One moment for our next question. It comes from Michael Petusky with Barrington Research. Your line is open.

Hey, good morning. I don't think this was addressed, but I just wanted to ask, and forgive me if it was. But was any aspect of the plasma number in Q1 sort of augmented by -- maybe the cadence of CSL orders sort of being front-end loaded?

No, just literally, the only effect was that order timing, Mike, which we had mentioned, and that was a fiscal 2022 order that lowered the fiscal 2023 first quarter demand. There was no order timing for this year. So just on a comparative basis this first quarter. The last of the easy comps, I guess, as they say.

Okay. All right. And then, I just want to -- I guess, sort of switch over real quick to Cardiva. Is there any way for you guys to quantify how much of the $27.2 million was Europe? Or is it just completely immaterial that figure?

It's really immaterial, Mike, at this stage. We have bold plans, but at this stage, it was really immaterial. The reality is -- and I think this is one of the things that's important to highlight on the strength of the first quarter and why we think it's a sneak peak, if you will, of the LRP to come. Both VASCADE and TEG will crest $150 million in annualized revenue this year. In the first quarter, both of them grew in the 20s, right, TEG in the lower to mid-20s and VASCADE in the high 20s. And so, we'll see how that plays out, but that was disproportionately driven by the U.S., which for -- as it is for most medical device companies is our highest gross margin business. So, the one-two combination in the hospital business was really powerful and drove both margin and total revenue growth for us. And we're excited about that. We are demanding that our international business deliver its fair share, and that may have a dilutive effect on margins as the year progresses, but we really benefited by it in the first quarter. And I think that's evidence of what those two workhorse product families can do for this company.

And then just one tiny clarification. I just want to make sure I understand. When you talk about hybrid in Italy and then in the future in Japan, are you talking about using both distributors and direct sales? Or are you just talking about using distributors in those markets?

For some products, yes, Mike, that's exactly right. And we'll grow. We're really nascent in those markets today. And so, I think we'll look at this and look at opportunities to scale the business. It is one of the biggest drivers of our operating leverage and our margin expansion over time, is getting to scale in those markets. If we can use distributors to help either on a permanent basis or on a transitional basis, that's what's built into the plan.

Yeah. Sorry, Chris, let me just be slow the uptake. So, are you using any direct sales in Italy or no?

Yes, small team where we have privileged account relationships.

Okay. Perfect. Thanks. Great quarter. Thank you.

Thank you, Mike.

Thank you. Our next question will come from Larry Solow from CJS Securities. Your line is open.

Great. Thanks. Good morning, guys, and I echo congrats on the good start to the year. Just any thoughts, Chris, I'm not sure if you touched this and I missed the beginning of the call, you probably haven't touched on it. But just your thoughts or commentary on the FcRn receptor space and obviously, some data early on, I guess, in July on CBP. Any just thoughts on that and how that could impact overall, plasma growth is obviously not near-term, but as we look out over the mid to long-term.

Yeah. Larry, thanks for the question. We have not talked about it. So, the anti-FcRn entree into -- more broadly into the autoimmune space is something we're watching closely. I should caveat that we don't have proprietary insight, right? We talk to all of our customers who are in these end markets. We talk to key opinion leaders. We read everything that is written about it, but we don't have proprietary insight. I would echo what I think you're hearing from our customers, which is with the ADHERE trial readout, it was -- congratulations to argenx. It was a successful trial. That's a good thing for patients, particularly given the inherent growth in demand for IG across primary, secondary and autoimmune diseases. So, we'll watch this carefully. We don't believe at this time that there's any reason to change the underlying forecast for growth in demand for IG, right, given there are 8,000 IG-based trials underway for those indications. So, we think it will clearly play a role, but it's unlikely to meaningfully cannibalize or compress the ultimate demand certainly in the near to intermediate term. But we'll watch and we'll update as we learn more. But from this point, we think it was useful to get the ADHERE data out there. Congratulations for that accomplishment. It's a good thing for patients, but we don't think it's going to have a disruptive effect on our trajectory.

Got it. Great. And then just a question just for James. So, it sounds like certainly the lower SG&A certainly benefit from some timing. Did you -- I know you don't maybe guide on gross margin specifically, but a pretty nice sequential improvement. I know it was down year-over-year. Should we view this number as a good starting point as we look out for the rest of the year? Or any color on that would be great. Thanks again.

Yeah. I would say, it's a fair starting point. I mean, we had a lot of ins and outs as well. It was also affected by the recall that we spoke about. We have the lingering temporary inefficiencies, which I had been previously talking about. But offsetting that, we had some very favorable mix and some improvement in price. So, we had a lot of ins and outs, but I think it's a pretty fair representation for the year.

Great. Thanks guys. Appreciate it.

Thank you. Our next question comes from Dave Turkaly with JMP Securities. Your line is open.

Hey, good morning, and congrats. Just wanted to follow-up on hemostasis. I think you mentioned pricing there. I don't really recall that in the past. But I know you had success device, but is there anything new there? Is there anything common that we should be looking for? And I guess, color around the pricing comment would be great. Thank you.

Hey, Dave. Thanks. With regards to Hemostasis Management, particularly here in the U.S., we have a robust portfolio of additional indications, additional cartridges to really tap into that broader total addressable market. And so, you see some of that benefit coming through. The first quarter was both equipment and disposables, but disproportionately disposables. Clearly, our margins on disposables are more favorable. So that's part of the pricing benefit. And then, we will continue to introduce, and we'll have more to say as the year progresses, new cartridges and new indications to broaden our leadership in that area. That's an area that we enjoy clear leadership market share and we intend to build and expand upon it. It will help price, but it will also help overall volume, too.

Thank you. End of Q&A:

Thank you. And there are no other questions in the queue. This does conclude today's conference call. Thank you for participating. You may now disconnect.